

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 9, 2025

PD-L1 (D5V3B) Rabbit mAb (Mouse Specific; IHC Specific)

RRID:AB_2799672

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 64988, RRID:AB_2799672)

Antibody Information

URL: http://antibodyregistry.org/AB_2799672

Proper Citation: (Cell Signaling Technology Cat# 64988, RRID:AB_2799672)

Target Antigen: PD-L1

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: IHC-Bond, IHC-P

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: PD-L1 (D5V3B) Rabbit mAb (Mouse Specific; IHC Specific)

Description: This monoclonal targets PD-L1

Target Organism: m

Clone ID: Clone D5V3B

Antibody ID: AB_2799672

Vendor: Cell Signaling Technology

Catalog Number: 64988

Record Creation Time: 20241016T234443+0000

Record Last Update: 20241017T011039+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development
<https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for PD-L1 (D5V3B) Rabbit mAb (Mouse Specific; IHC Specific).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Crump LS, et al. (2024) Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression. Cancer research communications, 4(3), 822.

Shang L, et al. (2024) Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers. Cell reports. Medicine, 5(7), 101648.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. Cell genomics, 4(10), 100659.

Pang L, et al. (2023) Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma. Cell reports. Medicine, 4(11), 101238.

Zhong W, et al. (2023) Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors. Cancer research, 83(16), 2790.

Liu XD, et al. (2023) SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(19), 4002.

Chen HA, et al. (2023) Senescence Rewires Microenvironment Sensing to Facilitate

Antitumor Immunity. *Cancer discovery*, 13(2), 432.

Martinez-Ordoñez A, et al. (2023) Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancer. *Cancer cell*, 41(2), 252.

Wu SY, et al. (2023) CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. *Med (New York, N.Y.)*, 4(6), 373.

Gaglia G, et al. (2023) Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma. *Cancer cell*, 41(5), 871.

Tobias J, et al. (2022) Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model. *Translational oncology*, 19, 101378.